Coronary calcification is associated with elevated serum lipoprotein (a) levels in asymptomatic men over the age of 45 years: A cross-sectional study of the Korean national health checkup data by 권혁문 et al.
Observational Study Medicine®
OPENCoronary calcification is associated with elevated
serum lipoprotein (a) levels in asymptomatic men
over the age of 45 years
A cross-sectional study of the Korean national health checkup
data
Young Hak Chung, MD , Byoung-Kwon Lee, MD, PhD, Hyuck Moon Kwon, MD, PhD, Pil-Ki Min, MD, PhD,
Eui-Young Choi, MD, PhD, Young Won Yoon, MD, PhD, Bum-Kee Hong, MD, PhD, Se-Joong Rim, MD, PhD,
Jong-Youn Kim, MD, PhD
∗
Abstract
Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular diseases. However,
the association between Lp (a) and CAC in asymptomatic individuals remains unclear. In this study, we aimed to determine the
influence of Lp (a) on CAC in asymptomatic individuals.
We included 2019 asymptomatic Korean adults who underwent testing for a coronary artery calcium score (CACS) and Lp (a) at
the GangnamSeverance Hospital Health CheckupCenter in Korea from January 2017 to August 2019. Participants were divided into
2 groups: CACS=0 and CACS>0. Factors affecting the CACS were analyzed by sex. Because age is a major risk factor for
atherosclerosis, ≥45years in men and ≥55years in women, we further divided participants into 4 subgroups (≥45 and <45 in men,
≥55 and <55 in women). Factors affecting the CACS in the 4 groups were analyzed.
There was a positive correlation between the CACS and traditional cardiovascular risk factors. Lp (a) positively correlated with the
CACS in men (P< .01) and remained significant after multivariable logistic regression (P< .01). The same result was observed in men
aged ≥45years (P< .01).
Lp (a) is an independently associated factor of CAC and a marker of coronary atherosclerosis in asymptomatic men aged ≥45
years. In asymptomatic men aged ≥45years, Lp (a) should be measured, and intensive Lp (a)-lowering treatment should be
considered.
Abbreviations: apo(a) = apolipoprotein (a), apoB-100 = apolipoprotein B-100, ASCVD = atherosclerotic cardiovascular disease,
BMI= bodymass index, CAC= coronary artery calcification, CACS= coronary artery calcium score, CAD= coronary artery disease,
CHD = coronary heart disease, CRP = C-reactive protein, CT = computed tomography, CVD = cardiovascular disease, EBCT =
electron-beam computed tomography, HDL-cholesterol = high-density lipoprotein cholesterol, LDL-cholesterol = low-density
lipoprotein cholesterol, Lp (a) = lipoprotein (a), MDCT = multi-detector computed tomography.
Keywords: atherosclerosis, cardiovascular risk factor, coronary artery calcium score, lipoprotein (a), multi-detector computed
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Cardiovascular disease (CVD) is the leading global cause of death
and is expected to account for >23.6 million deaths by 2030. In
addition, CVD and coronary heart disease (CHD) caused by
atherosclerosis were the leading causes of death in the United
States in 2015.[1] Although the development of new technologies
for the diagnosis and treatment of CVD and CHD has
considerably improved the clinical outcomes of patients, the
incidence of fatal cardiovascular events such as myocardial
infarction has still not decreased. Many studies have reported
that eliminating the risk factors associated with the occurrence of
CVD reduces the incidence of cardiovascular events caused by
atherosclerosis.[2] Approximately 50% of coronary deaths occur
in previously asymptomatic patients. For these reasons, it is
essential to identify the risk factors for CHD and CVD early and
to further assess the relationship between these risk factors with
the aim of reducing the incidence of fatal cardiovascular events.
Age, sex, smoking history, body mass index (BMI), hypertension,
diabetes mellitus, total cholesterol, low-density lipoprotein
cholesterol (LDL-cholesterol), and high-density lipoprotein
cholesterol (HDL-cholesterol) are conventional risk factors;
however, triglycerides, homocysteine, lipoprotein (a) (Lp (a)),
fibrinogen, and indices of inflammatory responses, such as C-
reactive protein (CRP), are also risk factors for CHD that may
provide additional information in the diagnosis of CVD.
Lp (a) is a lipoprotein that was discovered by Berg et al in
1963.[3] It consists of a lipid core composed of cholesteryl ester
and triglycerides, where apolipoprotein B-100 (apoB-100) is
bound to apolipoprotein (a) (apo(a)) with a characteristic
disulfide bond.[4] The apo(a) in Lp (a) is structurally similar to
plasminogen and is known to interfere with plasminogen’s
antithrombotic functions by competitively inhibiting the binding
of plasminogen to fibrin.[5] Lp (a) is composed of a moiety that is
essentially indistinguishable from LDL in both lipid composition
and the presence of apoB-100.[4] These characteristics suggest
that Lp (a) is involved in the process of atherosclerosis and
thrombogenesis. Many studies have reported the association
between Lp (a) and CHD[6–9]; therefore, Lp (a) has been
recognized as a cardiovascular risk factor by the European
Society of Cardiology and the European Atherosclerosis Society
guidelines.[10] However, unlike LDL-cholesterol, Lp (a) is still not
a primary target for therapeutic intervention.
With the development of computed tomography (CT) technol-
ogy, multi-detector CT (MDCT) was introduced in the late 1990s.
As a result of this technological advancement, cardiac CT has
become the main test for non-invasive assessment of coronary
atherosclerosis. It can provide comprehensive information about
the site of stenosis, the presence of non-stenotic coronary artery
stiffness, atherosclerotic plaque characteristics, and coronary
artery stenosis severity. The assessment of coronary artery stenosis
using cardiac CT has very high sensitivity and specificity – with a
95% to 99% negative predictive value – when compared to
invasive coronary angiography.[11] Because of the high accuracy
and non-invasive nature of this test, MDCT is included as part of
thehealth screeningprogram inmajorKoreanhospitals.[12] Several
studies have reported that the coronary artery calcium score
(CACS) measured using electron-beam computed tomography
(EBCT) is a specific marker of CHD and directly related to the
atherosclerotic plaque burden.[13] In addition, the CACS has also
shown to be valuable risk predictors of cardiovascular events in
patients with a high cardiovascular risk.[14] Nevertheless, studies2
that investigated the relationship between Lp (a) as a cardiovascu-
lar risk factor and the CACS as a specific marker of CHD have
reported contradictory results.[15,16]
If Lp (a) can predict coronary artery calcification (CAC) in
asymptomatic adults, a simple blood test can be used to evaluate
the CAC without a CT scan. In addition, intensive Lp (a)-
lowering therapy could prevent cardiovascular events in people
with a high Lp (a). For these reasons, we aimed to determine the
association between Lp (a) and the CACS in asymptomatic adults
using the large volume of data from the health screening program
in Korea.2. Methods
2.1. Study design and patient selection
Among 2858 patients with no cardiac symptoms who had
undergone a routine health examination at the Gangnam
Severance Hospital Health Checkup Center in Korea from
January 2017 to August 2019, a total of 2019 patients who had
both the CACS and serum Lp (a) measurements were selected for
this study. The participants were divided into those with CACS=
0 and CACS>0. First, factors affecting the CACS by sex were
analyzed. Because the risk of developing coronary artery disease
(CAD) increases with age, ≥45years in men and ≥55years in
women,[17] we divided the participants into 4 subgroups (≥45
and <45 in men, ≥55 and <55 in women). Second, the factors
affecting the CACS in the 4 subgroups were analyzed.2.2. Definition of variables
The following variables were investigated in all participants:
Hypertension was defined as antihypertensive drug use or having
a systolic blood pressure of ≥140mm Hg and/or diastolic blood
pressure of ≥90mm Hg. Diabetes mellitus was defined as the use
of hypoglycemic agents or insulin, a fasting plasma glucose level
of ≥126mg/dL, glycosylated hemoglobin (HbA1c) level of
≥6.5%, or known but untreated hyperglycemia. Hypercholes-
terolemia was defined as a total cholesterol level of >200mg/dL
or cases where the patient was treated with lipid-lowering drugs.
Smoking was defined as cases in which the subject was either
currently smoking or had a history of smoking in the past. Each
participant’s height and weight were measured, and BMI was
calculated as weight/height2 (kg/m2).2.3. Measurement of Lp (a)
After blood collection, plasma samples were immediately sent to
our laboratory and analyzed.
Lp (a) measurement was performed according to the latex
agglutination method with an anti-human Lp (a) monoclonal
antibody using a commercial kit [Lp (a) Daiichi Pure Chemicals
Co., Ltd] with an auto-analyzer (Hitachi 7600-110) that is not
affected by the different apo(a) isoforms.2.4. Coronary artery calcium scanning
CT scans were performed with a 64-MDCT scanner (Revolution
CT; GE Healthcare, Milwaukee, WI). All patients with an initial
heart rate ≥60beats/min were given an oral beta-blocker
(metoprolol, 40mg) to achieve a target heart rate of 50 to 60
beats/min. Sublingual nitroglycerin was administered immedi-
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volume (0.6–0.7mL/kg) of iodine contrast agent (iopamidol 370
mg iodine per milliliter, Iopamiro; Bracco, Milan, Italy) was
administered into the antecubital vein in 10seconds followed by
25mL of saline solution injected at 5.0mL/second. The CT-
reconstructed imaging data were transferred to a GE Centricity
system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) for
postprocessing and subsequent image analysis. The coronary
arteries were assessed with a rapid acquisition (100millisecond)
of 30 to 40 contiguous slices (each 3mm in thickness) during end-
diastole using an ECG-triggering method in a single 30 to 35
seconds breath-hold. A radiologist read each scan independently
at a centralized reading center. The quantitative CACS was
calculated according to the method described by Agatston
et al.[18] CACS>0 was defined as having a detectable CAC.2.5. Statistical analysis
Statistical analyses were performed using the Statistical Analysis
Software version 9.4 (SAS Institute Inc., Cary, NC). Continuous
data were presented as mean± standard deviation, and categori-
cal data were presented as percentages or the absolute number. In
cases of continuous variables, an independent t test was used for
comparison; for categorical variables, a chi-square test (Fisher’s
exact test) was used.We used logistic regression in the univariable
and multivariable models to determine the 95% confidence
intervals (CI) and odds ratios (OR) for the presence of CAC and
Lp (a) that adjusted for CAD risk factors including hypertension,
diabetes mellitus, smoking, BMI, and LDL-cholesterol. The
Turkey–Kramer post hoc test after Kruskal–Wallis test was used
to analyze the difference in the CACS according to serum Lp (a)
level. We also used the Wilcoxon rank-sum test to analyze theTable 1
Baseline characteristics of the groups divided by sex.
Men (n=1518)
Variables CACS>0 (n=763) CACS=0 (n=755)
Lp (a) (mg/dL) 16.63±20.44 13.82±16.06
Age (yr) 59.06±8.66 51.56±9.92
Smoking status
Non-smoker, n (%) 202 (26.47) 235 (31.13)
Smoker, n (%) 561 (73.53) 520 (68.87)
HTN
No, n (%) 387 (50.72) 552 (73.11)
Yes, n (%) 376 (49.28) 203 (26.89)
DM
No, n (%) 574 (75.23) 681 (90.20)
Yes, n (%) 189 (24.77) 74 (9.80)
Hypercholesterolemia
No, n (%) 200 (26.21) 261 (34.57)
Yes, n (%) 563 (73.79) 494 (65.43)
BMI (kg/m2) 26.12±3.39 25.95±3.51
Waist circumference (cm) 91.52±8.86 90.47±9.35
Total cholesterol (mg/dL) 197.55±46.59 206.13±38.44
Triglycerides (mg/dL) 160.30±107.47 152.34±89.27
HDL-cholesterol (mg/dL) 50.87±10.87 51.88±11.12




Continuous data are shown as mean±1SD. Dichotomous data are shown as n (%). BMI=body mass index,
hypertension, LDL= low-density lipoprotein, Lp (a)= lipoprotein (a), SD= standard deviation.
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effects of menopause on Lp (a) and CACS. A P value of<.05 was
considered statistically significant.3. Results
A total of 2019 asymptomatic Korean adults who underwent
health checkups were enrolled in this study, including 1518males
(75.2%). Differences in baseline characteristics between the 2
groups divided by sex are shown in Table 1. In males, the group
with CACS>0 (n=763) showed statistically significant differ-
ences (P< .05) in Lp (a), age, smoking, hypertension, diabetes
mellitus, hypercholesterolemia, total cholesterol, LDL-cholester-
ol, and waist circumference when compared to the CACS=0
group (n=755). Notably, Lp (a) levels were significantly higher in
the CACS>0 group (16.63±20.44 vs 13.82±16.06, P= .003).
In females (CACS>0, n=125; CACS=0, n=376), the 2
groups also showed statistically significant differences in age,
hypertension, diabetes mellitus, triglycerides, HDL-cholesterol,
BMI, waist circumference, and menopause (P< .05). However,
there was no significant difference in the Lp (a) level between the
CACS>0 and CACS=0 groups (18.97±21.92 vs 16.53±17.43,
P= .26).
Subsequently, we carried out a univariable logistic regression
for the 2 groups (Table 2) and multivariable logistic regression
after adjusting for Lp (a), smoking, hypertension, diabetes
mellitus, LDL-cholesterol, and BMI (Table 3). We found that Lp
(a) was significantly associated with the presence of CAC inmales
(95%CIOR 1.004–1.016, P= .001). However, in females, Lp (a)
did not show a significant correlation with the CACS (95% CI
OR 0.996–1.018, P= .23).
We divided our study cohort into 4 subgroups (≥45 or <45
years in men, and ≥55 or <55years in women) (Table 4).Women (n=501)
P CACS>0 (n=125) CACS=0 (n=376) P
.003 18.97±21.92 16.53±17.43 .26
<.001 63.39±8.05 54.20±9.33 <.001
.04 .60
110 (88.00) 324 (86.17)
15 (12.00) 52 (13.83)
<.001 <.001
52 (41.60) 294 (78.19)
73 (58.40) 82 (21.81)
<.001 <.001
95 (76.00) 352 (93.62)
30 (24.00) 24 (6.38)
<.001 .07
22 (17.60) 96 (25.53)
103 (82.40) 280 (74.47)
.32 25.44±3.63 24.07±4.04 <.001
.03 83.79±8.89 78.93±9.96 <.001
<.001 215.97±48.36 215.45±41.24 .91
.12 136.12±64.46 111.13±59.19 <.001
.08 56.94±12.41 61.38±13.73 .001
<.001 140.06±41.03 135.81±33.41 .30
<.001
25 (20.00) 180 (47.87)
100 (80.00) 196 (52.13)
CACS= coronary artery calcium score, DM=diabetes mellitus, HDL=high-density lipoprotein, HTN=
Table 2
Predictors of coronary artery calcium score by univariable logistic regression in the 2 groups.
Men (n=1518) Women (n=501)
Variables OR (95% CI) P OR (95% CI) P
Lp (a) 1.008 (1.003–1.014) .003 1.007 (0.996–1.017) .21
Age 1.091 (1.078–1.105) <.001 1.133 (1.100–1.168) <.001
Smoking 1.255 (1.004–1.568) .04 0.850 (0.460–1.570) .60
HTN 2.642 (2.132–3.274) <.001 5.033 (3.268–7.751) <.001
DM 3.030 (2.266–4.053) <.001 4.632 (2.586–8.294) <.001
Hypercholesterolemia 1.487 (1.193–1.854) <.001 1.605 (0.958–2.686) .07
BMI 1.015 (0.986–1.045) .32 1.087 (1.034–1.143) .001
Waist circumference 1.013 (1.001–1.024) .03 1.050 (1.029–1.072) <.001
Total cholesterol 0.995 (0.993–0.998) <.001 1.000 (0.996–1.005) .91
Triglycerides 1.001 (1.000–1.002) .12 1.006 (1.003–1.009) <.001
HDL-cholesterol 0.992 (0.983–1.001) .08 0.974 (0.958–0.990) .002
LDL-cholesterol 0.994 (0.991–0.997) <.001 1.003 (0.998–1.009) .25
Menopause 0.980 (0.938–1.025) .38
BMI=body mass index, DM=diabetes mellitus, HDL=high-density lipoprotein, HTN=hypertension, LDL= low-density lipoprotein, Lp (a)= lipoprotein (a), OR= odds ratio.
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showed a significantly higher Lp (a) level than the group
with CACS=0 (16.74±20.53 vs 13.97±16.10, P= .006). In
contrast, a significant difference in Lp (a) levels between the 2
groups was not found in males aged<45years (n=205), or either
subgroups of females (<55years (n=192) and ≥55years (n=
309)) (14.03±18.15 vs 13.31±15.97, P= .82, 16.48±22.59 vs
14.68±16.55, P= .70, 19.31±21.91 vs 18.16±18.06, P= .64,
respectively).
Subsequently, a univariable logistic regression (Table 5) and
multivariable logistic regression (Table 6) after adjusting for Lp
(a), smoking, hypertension, diabetes mellitus, LDL-cholesterol,
and BMI were carried out on the 4 subgroups. In males aged ≥45
years, Lp (a) was significantly associated with the presence of
CAC in both univariable and multivariable regression analyses
(95% CI OR 1.002–1.014, P= .008, 95% CI OR 1.003–1.016,
P= .003, respectively).
In contrast, Lp (a) did not show a significant correlation with
the CACS in univariable and multivariable regression analyses in
males aged<45years (95%CIOR0.980–1.026, P= .82, 95%CI
OR 0.973–1.023, P= .85, respectively), females aged <55years
(95% CI OR 0.978–1.034, P= .70, 95% CI OR 0.988–1.052,
P= .23, respectively), and females aged ≥55years (95% CI OR
0.991–1.015, P= .62, 95% CI OR 0.992–1.017, P= .53,
respectively).
In the analysis of the difference in the CACS according to
serum Lp (a) level (Fig. 1), the CACS was significantly higher in
the Lp (a) >50mg/dL group than in the 15 to 30mg/dL group
(P< .05).Table 3
Predictors of coronary artery calcium score by multivariable logistic
Men (n=1518)
Variables OR (95% CI)
Lp (a) 1.010 (1.004–1.016)
Smoking 1.181 (0.934–1.494)
HTN 2.334 (1.858–2.932) <
DM 2.588 (1.910–3.506) <
BMI 0.995 (0.964–1.027)
LDL-cholesterol 0.998 (0.995–1.001)
BMI=body mass index, DM=diabetes mellitus, HTN=hypertension, LDL= low-density lipoprotein, Lp
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We also analyzed the effects of menopause, one of the risk
factors for atherosclerosis, on Lp (a) and CACS (Fig. 2). We
found that the CACS and Lp (a) significantly differed among the
menopause groups (Yes or No) (P< .05).
4. Discussion
In the present study, we found that Lp (a) significantly correlated
with CAC in asymptomatic adult males, particularly in those
aged ≥45years, independent of traditional cardiovascular risk
factors, including hypertension, diabetes mellitus, smoking, LDL-
cholesterol, and BMI. These data imply that Lp (a) could
potentially play an important role as an independent risk factor
for CHD in asymptomatic adult males aged ≥45years. A
previous study of 861 asymptomatic relatives of patients with
premature atherosclerotic cardiovascular disease (ASCVD)
reported a clear relation between Lp (a) elevation and
atherosclerotic burden assessed by CACS.[19] Another study
involving a similar cohort to our study’s population found that
Lp (a) level was positively associated with a CACS>0 in the
highest quartile of Lp (a), suggesting a possible correlation
between Lp (a) level and CACS.[20] Our results are consistent
with these findings. However, we showed that Lp (a) is
independently associated with CAC in men, especially those
≥45years, who are a population at major risk of atherosclerosis.
In several studies, the CACS measured by MDCT predicted
future cardiovascular events in multiple populations. Further-
more, the CACS was able to detect coronary atherosclerosis and
improve the risk stratification of individuals beyond traditionalregression in the 2 groups.
Women (n=501)
P OR (95% CI) P
.001 1.007 (0.996–1.018) .23
.16 1.032 (0.531–2.005) .93
.001 4.374 (2.774–6.897) <.001
.001 3.536 (1.869–6.688) <.001
.76 1.048 (0.990–1.109) .11
.28 1.006 (0.999–1.012) .08
(a)= lipoprotein (a), OR= odds ratio.
Table 4
Baseline characteristics of 4 subgroups divided by sex and age.
Men (n=1518) Women (n=501)


















Lp (a) (mg/dL) 14.03±18.15 13.31±15.97 .82 16.74±20.53 13.97±16.10 .006 16.48±22.59 14.68±16.55 .70 19.31±21.91 18.16±18.06 .64
Smoking status .75 .25 .53 .07
Non-smoker, n (%) 11 (35.48) 67 (38.51) 191 (26.09) 168 (28.92) 13 (86.67) 137 (77.40) 97 (88.18) 187 (93.97)
Smoker, n (%) 20 (64.52) 107 (61.49) 541 (73.91) 413 (71.08) 2 (13.33) 40 (22.60) 13 (11.82) 12 (6.03)
HTN .03 <.001 <.001 <.001
No, n (%) 20 (64.52) 143 (82.18) 367 (50.14) 409 (70.40) 7 (46.67) 154 (87.01) 45 (40.91) 140 (70.35)
Yes, n (%) 11 (35.48) 31 (17.82) 365 (49.86) 172 (29.60) 8 (53.33) 23 (12.99) 65 (59.09) 59 (29.65)
DM .07 <.001 .03 <.001
No, n (%) 27 (87.10) 167 (95.98) 547 (74.73) 514 (88.47) 12 (80.00) 171 (96.61) 83 (75.45) 181 (90.95)
Yes, n (%) 4 (12.90) 7 (4.02) 185 (25.27) 67 (11.53) 3 (20.00) 6 (3.39) 27 (24.55) 18 (9.05)
Hypercholesterolemia .01 .01 .51 .87
No, n (%) 5 (16.13) 69 (39.66) 195 (26.64) 192 (33.05) 4 (26.67) 62 (35.03) 18 (16.36) 34 (17.09)
Yes, n (%) 26 (83.87) 105 (60.34) 537 (73.36) 389 (66.95) 11 (73.33) 115 (64.97) 92 (83.64) 165 (82.91)
BMI (kg/m2) 28.34±7.33 26.82±4.09 .27 26.03±3.09 25.68±3.27 .05 26.06±2.91 23.53±4.39 .03 25.36±3.72 24.56±3.64 .07
Waist circumference (cm) 93.90±14.99 91.39±10.96 .38 91.42±8.51 90.20±8.80 .01 83.90±7.82 76.55±9.84 .005 83.77±9.06 81.04±9.60 .02
Total cholesterol (mg/dL) 218.94±42.10 213.37±42.66 .50 196.65±46.58 203.96±36.84 .002 220.60±40.27 213.98±42.11 .56 215.34±49.48 216.75±40.52 .80
Triglycerides (mg/dL) 213.36±146.50 148.45±87.28 .02 158.05±105.05 153.50±89.90 .40 148.87±72.47 106.38±51.29 .04 134.38±63.46 115.35±65.26 .01
HDL-cholesterol (mg/dL) 48.39±10.27 51.86±11.38 .11 50.98±10.89 51.89±11.05 .14 53.60±13.31 61.36±13.70 .04 57.39±12.27 61.40±13.78 .01
LDL-cholesterol (mg/dL) 146.68±35.52 141.05±35.85 .42 126.66±37.53 132.76±30.21 .001 147.33±33.99 135.02±34.95 .19 139.06±41.94 136.51±32.05 .58
Menopause <.001 .83
No, n (%) 4 (26.67) 140 (79.10) 21 (19.09) 40 (20.10)
Yes, n (%) 11 (73.33) 37 (20.90) 89 (80.91) 159 (79.90)
Continuous data are shown as mean±1SD. Dichotomous data are shown as n (%). BMI=body mass index, CACS= coronary artery calcium score, DM=diabetes mellitus, HDL=high-density lipoprotein, HTN=
hypertension, LDL= low-density lipoprotein, Lp (a)= lipoprotein (a), SD= standard deviation.
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suggest that CACS assessment with CT may be considered a risk
modifier in the cardiovascular risk assessment of asymptomatic
individuals at low or moderate risk.[10] However, because of the
high costs and unavoidable radiation exposure involved in
determining the CACS, CT only has limited clinical value in the
screening of CAC in unselected individuals. Therefore, research-
ers now aim to identify a biomarker that can be easily measured
and become a suitable alternative to screening for CAC.[23,24]
Finding a biomarker that is associated with cardiovascular risk
and can predict CAC, particularly in asymptomatic individuals, is
a priority in cardiovascular disease prevention. The results of the
present study suggest that Lp (a) can be used as a biomarker to
predict CAC and screen men aged ≥45years who are
asymptomatic but expected to have a high CACS.Table 5
Predictors of coronary artery calcium score by univariable logistic re
Men (n=1518)
Age<45 (n=205) Age≥45 (n=1313
Variables OR (95% CI) P OR (95% CI)
Lp (a) 1.003 (0.980–1.026) .82 1.008 (1.002–1.014)
Smoking 1.138 (0.513–2.525) .75 1.152 (0.903–1.470)
HTN 2.537 (1.104–5.830) .03 2.365 (1.880–2.975)
DM 3.534 (0.969–12.891) .06 2.595 (1.914–3.517)
Hypercholesterolemia 3.416 (1.252–9.324) .02 1.359 (1.071–1.725)
BMI 1.060 (0.987–1.139) .11 1.035 (1.000–1.072)
Waist circumference 1.018 (0.986–1.050) .27 1.017 (1.004–1.030)
Total cholesterol 1.003 (0.994–1.012) .50 0.996 (0.993–0.999)
Triglycerides 1.005 (1.002–1.008) .003 1.000 (0.999–1.002)
HDL-cholesterol 0.971 (0.935–1.007) .12 0.992 (0.983–1.002)
LDL-cholesterol 1.004 (0.994–1.015) .42 0.995 (0.992–0.998)
Menopause
BMI=body mass index, DM=diabetes mellitus, HDL=high-density lipoprotein, HTN=hypertension, LD
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Lp (a) can be freely fluxed across the endothelial barrier
because of its small diameter,<70nm in length. It can be retained
similar to LDL-cholesterol within the arterial wall, which may
increase the risk of ASCVD. Lp (a) may also promote
atherosclerosis as it is a prominent carrier of proinflammatory
oxidized phospholipids.[25] Furthermore, it is suspected to be
prothrombotic based on the similarity of apo(a) to plasminogen
and may, therefore, interfere with plasminogen’s antithrombotic
functions.[26]
Lp (a) has already been identified as a predictor of
cardiovascular events in the 2002 PRIME Study.[6] In addition,
Lp (a) has been recognized as a cardiovascular risk factor by the
European Society of Cardiology and the European Atheroscle-
rosis Society guidelines.[10] In addition, several studies have
suggested that elevated serum Lp (a) levels are strongly andgression in the 4 subgroups.
Women (n=501)
) Age<55 (n=192) Age≥55 (n=309)
P OR (95% CI) P OR (95% CI) P
.008 1.006 (0.978–1.034) .70 1.003 (0.991–1.015) .62
.26 0.527 (0.114–2.433) .41 2.088 (0.918–4.751) .08
<.001 7.652 (2.535–23.103) <.001 3.427 (2.106–5.577) <.001
<.001 7.125 (1.583–32.074) .01 3.271 (1.707–6.269) <.001
.01 1.483 (0.453–4.851) .52 1.053 (0.563–1.968) .87
.05 1.114 (1.006–1.233) .04 1.061 (0.996–1.130) .07
.01 1.066 (1.016–1.118) .008 1.031 (1.006–1.057) .02
.002 1.004 (0.992–1.016) .56 0.999 (0.994–1.005) .79
.41 1.011 (1.003–1.019) .006 1.004 (1.001–1.008) .02
.14 0.955 (0.914–0.997) .04 0.977 (0.959–0.995) .01
.002 1.009 (0.995–1.023) .19 1.002 (0.996–1.009) .55
0.926 (0.840–1.021) .12 0.981 (0.929–1.037) .50
L= low-density lipoprotein, Lp (a)= lipoprotein (a), OR= odds ratio.
Table 6
Predictors of coronary artery calcium score by multivariable logistic regression in the 4 subgroups.
Men (n=1518) Women (n=501)
Age<45 (n=205) Age≥45 (n=1313) Age<55 (n=192) Age≥55 (n=309)
Variables OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Lp (a) 0.998 (0.973–1.023) .85 1.010 (1.003–1.016) .003 1.019 (0.988–1.052) .23 1.004 (0.992–1.017) .53
Smoking 0.924 (0.399–2.140) .85 1.143 (0.886–1.475) .30 0.380 (0.068–2.112) .27 2.381 (0.998–5.679) .05
HTN 2.252 (0.911–5.564) .08 2.116 (1.659–2.700) <.001 7.397 (2.250–24.318) .001 3.301 (1.962–5.555) <.001
DM 2.323 (0.501–10.771) .28 2.287 (1.668–3.136) <.001 8.073 (1.360–47.931) .02 2.701 (1.352–5.395) .005
BMI 1.023 (0.941–1.111) .60 1.017 (0.980–1.055) .38 1.131 (0.994–1.287) .06 1.017 (0.947–1.091) .65
LDL-cholesterol 1.006 (0.995–1.017) .31 0.999 (0.995–1.002) .41 1.010 (0.994–1.026) .22 1.005 (0.998–1.012) .18
BMI=body mass index, DM=diabetes mellitus, HTN=hypertension, LDL= low-density lipoprotein, Lp (a)= lipoprotein (a), OR= odds ratio.
Chung et al. Medicine (2021) 100:9 Medicinespecifically associated with an increased risk of CHD. Kwon et al
found that elevated Lp (a) levels have an incremental prognostic
value in type 2 diabetic patients with symptomatic CAD.[27]
Furthermore, in a large-scale cohort study conducted on 1560
European patients with suspected CHD (1123 men, age 59.3±
20.8years), the multivariable analysis revealed a strong indepen-
dent association between serum Lp (a) levels and the CACS.[15]
Qasim et al enrolled 1299 patients with type 2 diabetes mellitus
(480 women) and 860 patients without diabetes mellitus (403
women) and found that Lp (a) was associated with CAC in
diabetic women.[5]
Despite abundant evidence of causality, and the fact that one-
fifth of the general community has elevated Lp (a) levels >50mg/
dL,[28] Lp (a) has been considered a “conditional risk factor” that
is dependent on coexisting conditions and the individual’s
background such as age, ethnicity, sex, and diabetes, and thus,
not an “independent risk factor.”[5]
However, our findings suggest that Lp (a) should be considered
as an “independent risk factor” rather than a “conditional risk
factor,” and should be routinely measured for cardiovascular
assessment of asymptomatic men over the age of 45years.Figure 1. Difference in the coronary artery calcium score according to serum
Lp (a) level.
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Conversely, other studies have reported conflicting data on the
relationship between Lp (a) and the CACS. The GENOA study
conducted on 756 Caucasians found no association between Lp
(a) and the CACS.[29] Similarly, the multi-ethnic Dallas Heart
Study that studied 761 African Americans and 527 Caucasians
also found no clear association.[16]
In our study, we did not find an association between Lp (a) and
the CACS in males aged <45years or females of all age groups;
the exact reason for this is unclear; however, there may be several
reasons. The number of women (n=501) was one-third that of
men (n=1518), and additionally, there was a small number of
participants enrolled in 3 of the 4 age subgroups. The males ≥45
years subgroup (n=1313) accounted for over 60% of our sample
population. In the group of males aged <45years, the low
prevalence of CAC may have prevented the detection of
association. Cassidy et al found no association between the
presence of CAC and Lp (a) in females aged<55 years,[30] which
was consistent with our findings. Importantly, this is consistent
with the fact that the risk for atherosclerosis is higher in men, not
women, especially men over the age of 45years.
Although no significant results were found between Lp (a) and
the CACS in the female group, both Lp (a) and the CACS were
significantly increased in the postmenopausal group. This is
consistent with the well-known fact that serum Lp (a) levels
increase after menopause. Although it is expected that elevated
serum Lp (a) levels may be correlated with a higher incidence of
atherosclerosis in postmenopausal women, few studies have
analyzed the correlation between Lp (a) and the CACS in
asymptomatic postmenopausal women. In addition, a previous
study[31] did not show a significant correlation between Lp (a)
and the CACS. However, our findings show that Lp (a) may be
correlated with the CACS in asymptomatic postmenopausal
women. Further studies are needed to determine whether these
results are related to sex hormones.
In the case of LDL-cholesterol, which is a well-known
cardiovascular risk factor, our study showed that the group
with CACS>0 had a lower serum level of LDL-cholesterol than
the group with CACS=0. This is believed to be because more
subjects in the group with CACS>0 were receiving lipid-
lowering medication (15.1% vs 32.9%, data not shown).5. Limitations
There are several limitations to this study. First, this was
retrospective, single center, cross-sectional study. Therefore, we
could not show a causal relationship between Lp (a) and CACS.
Second, because of further categorizing participants into 4
Figure 2. Difference in the coronary artery calcium score and serum Lp (a) level according to the menopause groups.
Chung et al. Medicine (2021) 100:9 www.md-journal.comsubgroups, 3 groups, excluding the subgroup of males aged ≥45
years, included a very limited number of patients. Thus, our
findings cannot be applied to either the general population or
women. Third, as this study was conducted only on asymptom-
atic adults, there is a possibility that our analysis of the
association between serum Lp (a) level and CACS had less power
compared to that found in other studies.6. Further directions
To overcome these limitations, further studies involving a large
number of participants at multiple centers is required. In
addition, while CACS is a good marker for predicting CVD,
future studies should analyze CVD events together to confirm the
association between Lp (a), CACS, and CVD events.7. Conclusion
Lp (a) is an independently associated factor of CAC and amarker
of coronary atherosclerosis in asymptomatic men aged≥45years.
Therefore, Lp (a) should be measured, and intensive Lp (a)-
lowering treatment should be considered in this population.Acknowledgments
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